UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

Leukemia, 2010-01, Vol.24 (1), p.22-32

2010

Volltextzugriff (PDF)

Infinite deflectometry enabling 2π-steradian measurement range

Optics express, 2019-03, Vol.27 (5), p.7602-7615

2019

Volltextzugriff (PDF)

Non-arteritic anterior ischemic and glaucomatous optic neuropathy: Implications for neuroretinal rim remodeling with disease severity

PloS one, 2023-05, Vol.18 (5), p.e0286007-e0286007

2023

Volltextzugriff (PDF)

Response adaptive salvage treatment with daratumumab-lenalidomide-dexamethasone for newly diagnosed transplant-eligible multiple myeloma patients failing front-line bortezomib-based induction therapy-ALLG MM21

British journal of haematology, 2024-06

2024

Volltextzugriff (PDF)

A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells

Journal of translational medicine, 2019-07, Vol.17 (1), p.240-240, Article 240

2019

Volltextzugriff (PDF)

Response adaptive salvage with KTd and ASCT for functional high‐risk multiple myeloma—The Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial

British journal of haematology, 2023-08, Vol.202 (3), p.530-538

2023

Volltextzugriff (PDF)

Pathological Endogenous α-Synuclein Accumulation in Oligodendrocyte Precursor Cells Potentially Induces Inclusions in Multiple System Atrophy

Stem cell reports, 2018-02, Vol.10 (2), p.356-365

2018

Volltextzugriff (PDF)

Banking on virus-specific T cells to fulfill the need for off-the-shelf cell therapies

Blood, 2023-02, Vol.141 (8), p.877-885

2023

Volltextzugriff (PDF)

P14: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

HemaSphere, 2022-04, Vol.6 (Suppl), p.19-19

2022

Volltextzugriff (PDF)

P942: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

HemaSphere, 2022-06, Vol.6 (Suppl), p.832-833

2022

Volltextzugriff (PDF)

A sympathetic neuron autonomous role for Egr3-mediated gene regulation in dendrite morphogenesis and target tissue innervation

The Journal of neuroscience, 2013-03, Vol.33 (10), p.4570-4583

2013

Volltextzugriff (PDF)

A novel uncoupled ductile fracture criterion for prediction of failure in sheet metal forming

IOP conference series. Materials Science and Engineering, 2020-11, Vol.967 (1), p.12032

2020

Volltextzugriff (PDF)

Effects of material strain rate, impulse profile on damage evolution of steel plates subjected to repeated pressures

IOP conference series. Earth and environmental science, 2023-12, Vol.1278 (1), p.12028

2023

Volltextzugriff (PDF)

Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy

Clinical and experimental immunology, 2014-01, Vol.175 (1), p.49-58

2014

Volltextzugriff (PDF)

Comparison of the Charlson Comorbidity Index with the ASA score for predicting 12-month mortality in acute hip fracture

Injury, 2020-04, Vol.51 (4), p.1004-1010

2020

Volltextzugriff (PDF)

Direct C4 and C2 C–H Amination of Heteroarenes Using I(III) Reagents via a Cross Azine Coupling

Journal of organic chemistry, 2024-09, Vol.89 (18), p.13450-13456

2024

Volltextzugriff (PDF)

Linkage and association of the glutamate receptor 6 gene with autism

Molecular psychiatry, 2002-03, Vol.7 (3), p.302

2002

Volltextzugriff (PDF)

Linkage and association of the glutamate receptor 6 gene with autism

Molecular psychiatry, 2002-01, Vol.7 (3), p.302-310

2002

Volltextzugriff (PDF)

P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D‐RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT‐INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED ANALYSIS OF THE PHASE 3 MAIA STUDY

HemaSphere, 2023-05, Vol.7 (S2), p.14-15

2023

Volltextzugriff (PDF)

P30 SINGLE COHORT RESULTS FROM MAJESTEC‐2: TECLISTAMAB (TEC) IN COMBINATION WITH SUBCUTANEOUS DARATUMUMAB (DARA) AND LENALIDOMIDE (LEN) IN PATIENTS WITH MULTIPLE MYELOMA (MM)

HemaSphere, 2023-05, Vol.7 (S2), p.27-27

2023

Volltextzugriff (PDF)

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

The New England journal of medicine, 2019-05, Vol.380 (22), p.2104-2115

2019

Volltextzugriff (PDF)

Abnormal sympathetic nervous system development and physiological dysautonomia in Egr3-deficient mice

Development (Cambridge), 2008-09, Vol.135 (17), p.2949-2957

2008

Volltextzugriff (PDF)

P946: A PHASE I/II SINGLE ARM STUDY OF BELANTAMAB MAFODOTIN, CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: AMARC 19‐02 BELACARD STUDY

HemaSphere, 2022-06, Vol.6 (Suppl), p.836-837

2022

Volltextzugriff (PDF)

P907: CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS OF THE CANDOR STUDY

HemaSphere, 2022-06, Vol.6 (Suppl), p.798-799

2022

Volltextzugriff (PDF)

ZANUBRUTINIB PLUS OBINUTUZUMAB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)

Hematological oncology, 2019-06, Vol.37 (S2), p.121-122

2019

Volltextzugriff (PDF)

1 – 25 von 647

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(526)
Mit Volltextzugriff
(576)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(388)
Life Sciences & Biomedicine
(259)
Humans
(171)
Male
(105)
Female
(90)
Physical Sciences
(84)
Technology
(73)
Animals
(63)
Biological And Medical Sciences
(56)
Engineering
(56)
Middle Aged
(52)
Adult
(49)
Aged
(46)
Engineering, Electrical & Electronic
(43)
Medical Sciences
(39)
Medicin Och Hälsovetenskap
(39)
Optics
(35)
Telecommunications
(34)
Hematology
(30)
Mice
(30)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(41)
Hemasphere
(20)
Internal Medicine Journal
(11)
Clinical Lymphoma, Myeloma And Leukemia
(10)
Angewandte Chemie
(8)
Hematological Oncology
(8)
Nature Biotechnology
(8)
Plos One
(8)
Applied Physics Letters
(7)
British Journal Of Haematology
(6)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

Infinite deflectometry enabling 2π-steradian measurement range

Non-arteritic anterior ischemic and glaucomatous optic neuropathy: Implications for neuroretinal rim remodeling with disease severity

Response adaptive salvage treatment with daratumumab-lenalidomide-dexamethasone for newly diagnosed transplant-eligible multiple myeloma patients failing front-line bortezomib-based induction therapy-ALLG MM21

A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells

Response adaptive salvage with KTd and ASCT for functional high‐risk multiple myeloma—The Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial

Pathological Endogenous α-Synuclein Accumulation in Oligodendrocyte Precursor Cells Potentially Induces Inclusions in Multiple System Atrophy

Banking on virus-specific T cells to fulfill the need for off-the-shelf cell therapies

P14: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

P942: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

A sympathetic neuron autonomous role for Egr3-mediated gene regulation in dendrite morphogenesis and target tissue innervation

A novel uncoupled ductile fracture criterion for prediction of failure in sheet metal forming

Effects of material strain rate, impulse profile on damage evolution of steel plates subjected to repeated pressures

Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy

Comparison of the Charlson Comorbidity Index with the ASA score for predicting 12-month mortality in acute hip fracture

Direct C4 and C2 C–H Amination of Heteroarenes Using I(III) Reagents via a Cross Azine Coupling

Linkage and association of the glutamate receptor 6 gene with autism

Linkage and association of the glutamate receptor 6 gene with autism

P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D‐RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT‐INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED ANALYSIS OF THE PHASE 3 MAIA STUDY

P30 SINGLE COHORT RESULTS FROM MAJESTEC‐2: TECLISTAMAB (TEC) IN COMBINATION WITH SUBCUTANEOUS DARATUMUMAB (DARA) AND LENALIDOMIDE (LEN) IN PATIENTS WITH MULTIPLE MYELOMA (MM)

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

Abnormal sympathetic nervous system development and physiological dysautonomia in Egr3-deficient mice

P946: A PHASE I/II SINGLE ARM STUDY OF BELANTAMAB MAFODOTIN, CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: AMARC 19‐02 BELACARD STUDY

P907: CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS OF THE CANDOR STUDY

ZANUBRUTINIB PLUS OBINUTUZUMAB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)

Suchergebnisse filtern